Last reviewed · How we verify
NCT00001620
Screening for Hematology Branch Protocols
trial in Hematologic Disease and Disorders in 10,000 participants. Enrolling by invitation.
Quick facts
| Lead sponsor | National Heart, Lung, and Blood Institute (NHLBI) |
|---|---|
| Status | ENROLLING BY INVITATION |
| Study type | OBSERVATIONAL |
| Enrollment | 10,000 |
| Start date | 31 December 1996 |
| Sites | 1 location across United States |
Conditions studied
- Hematologic Disease and Disorders — all drugs for Hematologic Disease and Disorders →
- Donors — all drugs for Donors →
- Healthy Volunteer — all drugs for Healthy Volunteer →
Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Who can join
Adults 2 to 100, any sex, with Hematologic Disease and Disorders or Donors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study allows the evaluation of subjects in order to determine their ability to safely participate in other active research studies. After subjects complete the screening process, they will be offered the opportunity to participate in an active research study, or if no appropriate studies are available information and recommendations will be provided for other treatment options....
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Single-cell RNA-seq reveals a distinct transcriptome signature of aneuploid hematopoietic cells.
Zhao X, Zhao X, Gao S, Wu Z, et al · · 2017 · cited 52× · PMID 29030335 · DOI 10.1182/blood-2017-08-803353 -
Early activation of inflammatory pathways in UBA1-mutated hematopoietic stem and progenitor cells in VEXAS.
Wu Z, Gao S, Gao Q, Patel BA, et al · · 2023 · cited 49× · PMID 37586319 · DOI 10.1016/j.xcrm.2023.101160 -
The Spectrum of Hepatic Involvement in Patients With Telomere Disease.
Kapuria D, Ben-Yakov G, Ortolano R, Cho MH, et al · · 2019 · cited 47× · PMID 30791107 · DOI 10.1002/hep.30578 -
Circulating S100A8 and S100A9 protein levels in plasma of patients with acquired aplastic anemia and myelodysplastic syndromes.
Giudice V, Wu Z, Kajigaya S, Fernandez Ibanez MDP, et al · · 2019 · cited 37× · PMID 29958797 · DOI 10.1016/j.cyto.2018.06.025 -
Sequencing of RNA in single cells reveals a distinct transcriptome signature of hematopoiesis in GATA2 deficiency.
Wu Z, Gao S, Diamond C, Kajigaya S, et al · · 2020 · cited 33× · PMID 32556286 · DOI 10.1182/bloodadvances.2019001352 -
Long noncoding RNAs of single hematopoietic stem and progenitor cells in healthy and dysplastic human bone marrow.
Wu Z, Gao S, Zhao X, Chen J, et al · · 2019 · cited 30× · PMID 30545929 · DOI 10.3324/haematol.2018.208926 -
Bone marrow skeletal stem/progenitor cell defects in dyskeratosis congenita and telomere biology disorders.
Balakumaran A, Mishra PJ, Pawelczyk E, Yoshizawa S, et al · · 2015 · cited 27× · PMID 25499762 · DOI 10.1182/blood-2014-06-566810 -
Differential diagnosis of bone marrow failure syndromes guided by machine learning.
Gutierrez-Rodrigues F, Munger E, Ma X, Groarke EM, et al · · 2023 · cited 23× · PMID 36542832 · DOI 10.1182/blood.2022017518
Verify or expand the search:
- PubMed search for NCT00001620
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hematologic Disease and Disorders
Currently open trials in the same condition.
- NCT06828796 — Early Use of Tacrolimus in HLA-Mismatched Haploidentical Allogeneic Hematopoietic Transplantation With Post-Transplant C · Phase 2 · recruiting
Other National Heart, Lung, and Blood Institute (NHLBI) trials
Trials by the same sponsor.
- NCT07566494 — Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease · Phase 1 · not yet recruiting
- NCT07137455 — EDEN Intracardiac Electrogram Recording and Classifying System · NA · enrolling by invitation
- NCT05372627 — NHLBI-Emory Advanced Cardiac CT Reconstruction · not yet recruiting
- NCT07516379 — GRAfT 2.0. A Multimodal Prospective Approach to Define the Mechanisms and Clinical Features of Acute and Chronic Rejecti · not yet recruiting
- NCT06948097 — Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fost · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00001620 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Heart, Lung, and Blood Institute (NHLBI)
- Last refreshed: 8 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00001620.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing